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Introduction
Heart failure is defined as a pathophysiological
state in which an abnormality of cardiac function is
responsible for the failure of the heart to pump blood
at a rate commensurate with the requirements of the
metabolising tissues and/or to be able to do so only
from an elevated filling pressure.' This abnormality
in cardiac function is reflected by the occurrence of
exercise intolerance. Although heart failure is known
for a long time in medical history, this condition is
still associated with high morbidity and mortality.
Various studies have demonstrated around 50%
mortality rate over 2-5 years or an annual mortality
rate of about 25% in patients with left ventricular
dysfunction.2"3 In addition, repeated hospital-isation
for treatment of worsening heart failure has placed a
severe strain on the health care system. In this
article, the preventive and treatment strategies
currently available for the management of heart
failure will be discussed.
Keywords: Heart failure, aetiology, diagnosis,
management
Aetiology
In North America, between 60-70% of adult
patients with heart failure have left ventricular
dysfunction secondary to ischaemic heart disease, and
nonischaemic dilated cardiomyopathy accounts for
approximately 20% of patients with heart failure.4 In
Hong Kong, coronary artery disease is now the most
common cause of heart failure. This is due to the
increasing incidence of coronary artery disease as
society becomes more westernized, the increasing
proportion of the elderly in the population and
improved survival in patients with established heart
failure and myocardial infarction. Hypertensive
cardiovascular disease is probably the second most
common cause. On the other hand, congestive heart
failure (especially refractory right heart failure)
resulting from rheumatic valvular problems still
remains an important disease. Idiopathic dilated
cardiomyopathy, post-viral myocarditic
cardiomyopathy, undiagnosed / inoperable congenital
heart disease, untreated chronic tachyarrhythmia are
some of remaining causes for patients hospitalised for
heart failure.
Pathophysiology of Heart Failure
Heart failure is associated with changes
involving the heart as well as the peripheral
circulatory system (Figure 1). The initial insult is
usually an abnormal increase in after-load or
significant loss of functioning myocardium.
Development of myocellular hypertrophy and
alterations in collagen matrix occur which ultimately
results in geometric changes (remodelling) of the left
ventricle and reduced cardiac output. During this
process, baroreflex responses are attenuated and a
variety of neurohormonal systems are activated.
Some of the vasoconstrictor neurohormone systems,
i.e. the sympathetic nervous system, angiotensin II,
aldosterone and endothelin, may also act directly on
*Address for correspondence: Dr. C.P. Lau, Reader and Chief of Division of Cardiology, Department of Medicine, University of Hong
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the heart by further increasing cellular hypertrophy,
collagen synthesis and promoting increased cytosolic
calcium. These actions create a cycle within the
heart resulting in increased myocardial energy
expenditure, hastening cell injury and induction of
lethal arrhythmias. These neurohormones also induce
systemic arterial and venous vasoconstriction,
vascular remodelling and endothelial dysfunction.
These effects increase the afterload to the heart and
promote salt and water retention in the kidney,
leading to circulatory congestion. Altered blood flow
to the skeletal muscle and diminished baroreceptor
response to stress and pulmonary congestion further
contribute to decreased exercise performance.5'7 The
overall effects will be clinically manifested by an
elevation in left ventricular end-diastolic pressure,
low cardiac output state, peripheral oedema and
dyspnoea, and these adaptive cardiac and non-cardiac
changes further worsen heart failure. Although other
neurohormones such as the natriuretic peptides and
some prostaglandins are vasodilatory and natriuretic,
the extent of the modulation is usually not sufficient
to break the aforementioned vicious cycles, especially
in the advanced stage of the disease.
Figure 1: The Pathophysiology of heart failure involves the Interaction of Intrinsic Cardiace Function with
Neurohormonal Activation, Peripheral Vasoconstriction and Volume expansion. Clinical Effects
are Encircled.
j Preload «-
Cardiac remodelling
I Cardiac output
RAS = Renin Angiotensin System, SNS = Sympathetic Nervous System
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Systolic / Diastolic Dysfunction Clinical Findings in Heart Failure
The majority of patients with chronic heart
failure will have elements of both systolic and
diastolic dysfunction. The hallmark of systolic
dysfunction is a reduced cardiac ejection fraction
due to myocardial injury or cell death. Systolic
dysfunction is likely to be the predominant
problem in patients with previous myocardial
infarction or idiopathic dilated cardiomyopathy.
Diastolic dysfunction reflects changes during the
diastolic period and includes alterations in
myocardial relaxation (reflected by changes in
early diastole), and ventricular compliance
(reflected by changes later in diastole). Since
diastolic relaxation is not a passive process but
requires energy, diastolic dysfunction may result
from any condition where myocardial demands
exceed supply e.g. myocardial ischaemia.
Ventricular interdependence and pericardial
restraint will also influence diastolic function as
in cases of restrictive cardiomyopathy and
constrictive pericarditis.8
Most of the recent large mortality trials in
heart failure have enrolled patients with
predominant systolic dysfunction, providing new
insights for their management. However, the
definitive treatment of patients with diastolic
dysfunction remains controversial. On the other
hand, increased left ventricular mass and
hypertrophy are still important determinants of
impaired ventricular filling, a decrease in left
ventricular wall thickness and mass appears to be
a rational objective of treatment of diastolic
ventricular failure. Angiotensin converting
enzyme inhibitors, calcium channel blocking
agents, beta-adrenergic blocking drugs and
centrally acting sympatholytic agents have been
shown to be potentially effective in reducing left
ventricular mass. However, in patients with
overt heart failure, diuretic therapy will be
needed,9 but excessive diuresis may be
detrimental as left ventricular filling is now
dependent on a higher than normal filling
pressure.
In severe heart failure, symptoms will usually
be obvious and generally include fatigue, dyspnoea,
peripheral oedema, orthopnoea, paroxysmal
nocturnal dyspnoea, cough, weight gain, abdominal
discomfort, and cool extremities. Patients with less
severe heart failure may be asymptomatic at rest
and have only modest limitation in activities. The
New York Heart Association (NYHA) classification
is widely used to grade the degree of symptoms of
adult heart failure patients (Table 1).
Table 1: New York Heart Association
Classification of Heart Failure
Class I No symptoms
Class II Symptoms with ordinary activity
Class III Symptoms with less than ordinary activity
Class IV Symptoms at rest
Nevertheless, symptoms might not always
correlate with severity of left ventricular
dysfunction. Sometimes, patients with severe left
ventricular systolic dysfunction still remain
relatively asymptomatic; and bear in mind the fact
that prognosis of patients with heart failure depends
very much on residual left ventricular function
(ejection fraction) rather than heart failure
symptoms.
On physical examination in patients with
severe heart failure, a low or normal blood
pressure may be found. Sinus tachycardia (heart
rate above 100 beats/min) is common, and pulsus
alternans may be present, The periphery may be
characteristically cool with oedema of varying
degrees. Patients may be diaphoretic and appeal
cyanotic. The lung signs include tachypnoea,
crackles, wheezing and pleural effusion. Palpation
of the cardiac apex usually reveals a displaced apex
laterally. Tachycardia, gallop rhythms (S3 and SJ
and murmurs of mitral regurgitation are very
common. In severe cases of right sided failure,
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tricuspid regurgitation is present, the jugular venous
pressure is elevated and hepatojugular reflex is
positive. Hepatosplenomegaly, and occasionally
ascites, may be observed.
Chest radiography will characteristically show
cardiomegaly, the presence of interstitial oedema,
vascular redistribution, peribronchial cuffing and
pleural effusions. Calcification of the aortic or
mitral valves may be present, as well as
calcification in a left ventricular aneurysm.
ECG findings vary considerably. Atrial
fibrillation and atrial flutter are common as are
supraventricular and ventricular ectopic beats.
Nonspecific ST-T wave changes may occur, and it is
not uncommon to find evidence of an old myocardial
infarction or left ventricular hypertrophy. Prior Q
wave myocardial infarction (Figure 2), particularly
in two different regions, suggest systolic dysfunction,
while left ventricular hypertrophy may be associated
with diastolic dysfunction. A complete left bundle
branch block may represent an underlying
cardiomyopathy or may obscure underlying Q waves
from prior myocardial infarction.
Complete blood count is useful to exclude
anaemia. A haemoglobin below 9 g/dL may
precipitate or aggravate congestive heart failure.
Serum sodium is an excellent and inexpensive
test that indicates neurohormonal activation.
Sodium level is also inversely proportional to
plasma renin level10 and the lower the sodium, the
higher the renin and the worse the prognosis for
survival. Serum potassium is also important.
Maintenance of a potassium level on the high side
e.g. 4.0 to 5.0 mmol/L is recommended, as the
serum potassium underestimates intracellular
potassium level. The lower the potassium, the
worse the prognosis, and the same holds true for
magnesium." Renal function is often abnormal in
patients with severe heart failure. Both urea and
creatinine may continue to increase with
deteriorating left ventricular function and the need
for high dose diuretic therapy. Serum electrolytes
and uric acid are frequently altered by diuretic
therapy. Severe right-sided heart failure may
impair liver function. A thyroid function test is
important to exclude thyroid dysfunction as a cause
of heart failure (Table 2).
Figure 2: Patient with Old Extensive Anterior Myocardial Infarction and Left Ventricular Aneurysmal
Dilatation
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Table!: Diagnostic and
Investigations
Evaluation
Laboratory Tests:
Non-invasive Tests:
Invasive Tests:
Complete Blood Picture
RFT, LFT, urate
Thyroid Function Test
CXR, ECG
Echocardiography
Exercise Testing
Radionucleide Imaging
Haemodynamic Monitoring
Cardiac Catheterisation
+/- Biopsy
Cardiac Diagnostic Tests
Non-Invasive
Objective noninvasive assessments of cardiac
performance are indicated in all patients with known
or suspected heart failure. The data obtained by
these techniques help to differentiate systolic from
diastolic dysfunction, exclude other causes of
dyspnoea such as pulmonary diseases and are
predictive of outcome and may guide the selection of
therapy in individual patients. Each technique
provides different kinds of information, and
depending on the specific information sought, one or
the other test may be performed.
Echocardiography is imperative in patients with
heart failure to provide a low cost, comprehensive,
noninvasive diagnostic and prognostic assessment
with measurement of ventricular function, chamber
dimension, muscle mass, valvular function, detection
of intracardiac thrombus or masses, and indirect
estimation of cardiac haemodynamics12 (Figure 3).
Figure 3: Two-dimensional Echocardiography in
a Patient with Dilated Cardiomyopathy
(Ejection Fraction = 35%)
(a) Systole
(b) Diastole
Radionuclide angiography is recommended in
patients with heart failure as an accurate,
reproducible noninvasive technique for measurement
of ventricular function and left ventricular ejection
fraction.13 The myocardial stress thallium imaging
(either induced by exercise or by pharmacological
means) is frequently employed to look for reversible
myocardial ischaemia in patients with heart failure.
This imaging technique may be particularly useful
when revascularisation procedures are being
considered in heart failure patients.14
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An exercise test, especially coupled with
cardiopulmonary assessment, may be used to exclude
irreversible causes of heart failure. In addition, this
also helps to confirm a diagnosis of limited functional
capacity, to assess major limiting symptoms, to
monitor response to therapy or to prescribe
appropriate level of daily activities.
Invasive
In critically ill patients, clinical assessment of
the severity of the haemodynamic abnormalities is
frequently inaccurate and haemodynamic monitoring
may confirm the mechanism and the severity of the
low output state. However, haemodynamic
monitoring is usually not required for the initiation of
therapy with vasoactive drugs in patients with stable
chronic heart failure.16
Coronary angiography is not routinely required
in patients with congestive heart failure. Most
patients in whom left ventricular dysfunction are
secondary to coronary artery disease have had a
previous myocardial infarction and, therefore, the
primary diagnosis of their condition is usually not in
doubt. Patients who present with anginal symptoms
despite medical therapy or documented evidence of
myocardial ischaemia should undergo a complete
evaluation including coronary angiography, and an
indication for myocardial revascularisation should be
determined. In some cases, the aetiology of the
cardiomyopathy may be uncertain, and this must be
established by coronary angiography.
At present, routine endomyocardial biopsies are
not recommended in patients with dilated
cardiomyopathy since the likelihood of making
diagnoses of treatable disease is too low to justify the
small risk of cardiac perforation. In addition,
endomyocardial biopsies are not indicated in patients
with suspected myocarditis because the frequency of
diagnostic biopsies is low and there are no convincing
data to support the use of immunosuppressive
therapy. However, endomyocardial biopsies are
recommended for the diagnosis of cardiac lesions in
which there are known therapies, and when the
diagnosis cannot be made reliably without a cardiac
biopsy e.g. diagnosis of cardiac allograft rejection.17
The prognostic indicators of heart failure are
summarized in Table 3. The functional state of the
patients and exercise capacity are excellent indicators
of survival.
Table 3: Prognostic Indicators of Survival in
Heart Failure
• Functional Class
• Exercise Capacity and Maximum Oxygen Consumption
• Presence of Residual Ischaemia
• Serum Sodium
• Serum Catecholamines
• Ejection Fraction
Medical Treatment of Heart Failure
General
The goals of treatment of heart failure are to
reduce symptoms, decrease the need for repeated
hospitalisations and improve survival. In addition,
the factors which precipitate or aggravate heart
failure should be recognised and managed in concert
with the heart failure. The role of a Cardiac
Rehabilitation Programme is well recognised, and has
been documented to reduce reinfarction and exercise
performance in patients with heart failure. In short,
it is a programme that concentrates various faculties
such as doctors, nursing staff and allied health
professionals to give a more efficient services. The
aims of the program include: firstly, risk factors
modification in patients with established coronary
artery disease; secondly, education and counselling of
patients and family members on the understanding of
disease and finally, the advisability of light regular
activity commensurate with patients' functional
capacity. Structured exercise programmes improve
exercise capacity and decrease symptoms, although
the long term efficacy in survival remains to be
studied.
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Diuretics
Diuretics remain useful for management of heart
failure.18 The principal mechanism of action is to
reduce excessive salt and water retention with a
reduction in preload, which results in a decrease in
symptoms from pulmonary and systemic congestion.
Most symptomatic patients will require diuretic
therapy, may be in low doses, and combination
diuretic therapy is helpful in refractory heart failure.
It is conventional to use a potassium sparing agents
before stepping up high dose loop diuretic.
Furthermore, such combination diuretic therapy may
ensure a more efficient diuresis since they act on
different sites of the renal tubular system.
Nevertheless, major adverse effects include excessive
reduction in preload with reduced cardiac output,
aggravation of fatigue, electrolyte disturbances,
prerenal renal failure and neurohormonal activation
may be harmful in patients. The possibility of
inducing hyperkalaemia and further renal dysfunction
when using combination diuretic therapy together
with the almost ubiquitous use of angiotensin
converting enzyme (ACE) inhibitor should be
considered. The optimal dose of diuretic is
determined by minimal oedema and congestion
without compromising the cardiac filling pressure.
This is determined by a jugular venous pressure of
<8 cm of water and absence of significant
hepatojugular reflex and prerenal azotaemia (Table
4). Patients should keep daily charts of their optimal
body weight and serum electrolytes should be closely
monitored.
Table 4: Diuretics - Practice Points
• Thiazide diuretics not useful if creatinine clearance < 30
ml/min
• Frusemide should be started at 20-40 mg/day. Single dose
up to 160 mg/day more effective than divided doses
• AviodNSAID
• Monitor potassium level twice weekly until stable (aim at
>4 mmol/l)
• Monitor daily body weight (optimum wt: JVP < 8 cm, no
HJ reflex)
ACE Inhibitors
ACE inhibitor therapy has been shown to reduce
mortality, improve quality of life (decrease
hospitalisation, increase exercise tolerance) and
reduce the risk of myocardial infarction in patients
with NYHA class II to IV congestive heart failure.19'
21
 Patients with the lowest ejection fractions and
worst symptoms derive the most benefit. In
asymptomatic patients with left ventricular
dysfunction, ACE inhibitors can also prevent
deterioration to overt heart failure and prevent
myocardial infarction in patients with LVEF 35 % or
less.22 In the early post infarct period22"26, as well as
in the days after, starting ACE inhibitors have been
shown to decrease mortality, prevent progression to
overt heart failure and to reduce the risk of recurrent
myocardial infarction.27"29 The improvement in both
short-term and long-term outcome suggests that the
benefit of ACE inhibitors may not be due entirely to
an attenuation of ventricular remodelling, which
could be expected to occur over a long period, thus
it is postulated that most of the benefit is achieved
through a primary cardioprotective effect as well as
through the prompt blockade of the deleterious effects
of neurohumoral activation.30"31 Side effects of ACE
inhibitors include cough, hypotension (especially
first-dose effect), angioedema, altered taste sensation,
skin rash and rarely, reversible bone marrow
suppression. Patients at greatest risk of worsening
renal function and hyperkalaemia include those with
bilateral renal artery stenosis, renal impairment and
hypertension. Though ACE inhibitors has been
shown to differ in affinity for receptors in cardiac
and peripheral tissues, these significance requires
further evaluation and their preferred use in
particular clinical situations e.g hypertension need
further study;32"33 but the consensus still hold that
ACE inhibitors appear largely interchangeable, the
efficacy seem to be a class effect rather than the
action of a particular prototype. Similarly, the issue
on which dosage of ACE inhibitor should be used
clinically remain disputed and certainly await further
studies (such as the latest ATLAS trial which assess
the efficacy of different doses of ACE inhibitors in
the management of heart failure). However, the
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appropriate doses used in these large mortality trials
can be used as initial guidelines. Practical points for
the usage of ACE inhibitors are listed in Table 5.
Table 5: ACE Inhibitors - Practice Points
• Exclude volume depletion:
orthostatic hypotension, prerenal azotaemia, metabolic
alkalosis
• First dose hypotension and elderly:
test dose e.g. 6.25 mg captoprll (or 2.5 mg enalapril)
then 12.5 mg tds
• Monitor weekly for:
increase in serum creatinine (>40 umol/l)
potassium level > 5.5 nanol
symptomatic hypotension
• Efficacy may occur only after several months
• Consider hydrallazine/isosorbide if ACE Inhibitors not
tolerated
• Dose: captopril 2.5 mg tds to 50 mg bd
enalapril 2.5 mg Qd to 10 mg bd
If serum creatinine >250 umol/l — half dose
• Cough: may be due to worsening heart failure
reduce dose and reassurance, try anti-tussive
• Avoid potassium-sparing diuretics
Other Vasodilators
Losartan, an orally active, non-peptide
angiotensin II receptor antagonist has been introduced
to provide pharmacological blockade of the renin-
angiotensin-aldosterone system. Its effect on blood
pressure, renal function, systemic and regional
haemodynamic effects seems comparable to ACE
inhibitors.34 The main advantages of Losartan over
ACE inhibitors are firstly, the adverse effects seen
with ACE inhibitors that are attributed to non-renin
angiotensin system effects (notably angioedema and
cough) may be less frequent in patients treated with
a selective angiotensin II receptor blocker. Secondly,
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enzymes have been described which are capable of
producing angiotensin II via metabolic pathways
independent of the classical renin-angiotensin system
route, thus bypassing the action of ACE inhibitors.
Losartan, being an angiotensin II receptor blocker,
can antagonise the effects of the end-product
(angiotensin II) specifically.35"37 In clinical studies,
there are supporting evidence that short-term
administration of Losartan in patients with
symptomatic heart failure has resulted in beneficial
haemodynamic effects.38 Though its long term
benefits especially on importance in survival awaits
further studies for documentation. Nevertheless,
Losartan may be an alternative to patients who cannot
tolerate ACE inhibitors because of their side effects.
Hydrallazine and nitrates in combination
improve exercise tolerance and appear to improve
survival in patients with NYHA class II to III heart
failure39, though this drug combination is not well
tolerated in as most as one-third of patients.
Furthermore, the improvement in survival appears to
be less than with ACE inhibitors.40 Therefore, they
may be used as an alternative for patients who are
intolerance of ACE inhibitors. Whether these could
be used in combination with ACE inhibitors remain
uncertain.
First-generation calcium channel blockers
(nifedipine, diltiazem, verapamil) are not
recommended for routine use in patients with systolic
dysfunction;41"42 newer agents (amlodipine, felodipine
and nicardipine) are being assessed in ongoing
clinical trials but are also not recommended for
routine use in heart failure.43"44 There is no data
concerning the role of other vasodilators such as
prazosin, minoxidil and alpha-methyl-dopa.
Digitalis and Other Inotropic Drugs
The use of positive inotropic agents in patients
with heart failure has been the subject of great
controversy. The variety of agents that have been
proposed are generally classified as digitalis
glycosides or nonglycosides, and the latter includes
(Continued on page 530)
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phosphodiesterase inhibitors, beta-adrenergic receptor
agonists and dopaminergic-receptor agonists. In view
of their haemodynamic profile, the phospho-
diesterase inhibitors initially appeared to be a
welcome addition to therapies for heart failure, but
subsequent clinical trials with drugs such as milrinone
and enoximone indicated that these agents were not
only of no benefit, but had an adverse effect on
survival.45"46 These drugs continue to be used
intravenously to treat acute haemodynamic situations
but they have no role in the long term management
of heart failure.
The parent dopaminergic agents, dobutamine and
,dopamine, are only of limited value in the long term
management of heart failure, primarily because of
their mandatory intravenous route of administration.
Intermittent administration, either as in out-patient or
during brief hospital admission, has resulted in
haemodynamic improvement, questionable
improvement of symptoms and no improvement on
survival.47'48 Ideally, dobutamine should be
administrated initially in a hospital intensive care unit
setting and a dose-response curve constructed using
haemodynamic monitoring. The usual starting dose
is 2.5 ug/kg/min and the dose titrated to optimise
cardiac index. Although up to 15 ug/kg/min may
occasionally be acutely used, 80% of the maximum
haemodynamic response is generally observed at 6 to
8 ug/kg/min - the usual dose used for home
intravenous therapy. A recent study suggested that
by avoiding a high dose, dobutamine appears to be
well tolerated and may significantly improve
symptoms.49
In patients with atrial fibrillation and left
ventricular failure, digoxin should be the initial agent
used for this clinical situation because both beta-
blockers and/or calcium channel antagonists may
have negative inotropic effects and therefore be
relatively contraindicated. However, the inability of
digoxin to control exercise-induced tachycardia
adequately in this clinical setting often requires the
addition of one of these agents. In patients with
sinus rhythm, a large body of evidence indicates
indirectly that digoxin is useful in improving
symptoms, increasing exercise tolerance, improving
the ejection fraction, and will result in clinical
deterioration when discontinued;50^3 one of which
was the RADIANCE Trial, which studied patients
with NYHA functional class II or III heart failure and
an ejection fraction < 35 % who were clinically stable
while receiving digoxin, diuretics and an ACE
inhibitor. Patients were randomised to either
continue digoxin therapy or receive placebo for 12
weeks. Digoxin withdrawal was associated with
significant clinical deterioration, including reduction
in exercise time, an increased need for emergency
care/ hospitalisation for decompensated heart failure
and a lower quality of life score. Nevertheless, the
issue of whether digoxin prolongs life in patients with
heart failure remains to be answered, but is the prime
outcome being tested in the ongoing Digoxin
Investigation Group (DIG) mortality trial in 1995
(Table 6).
Table 6: Digoxin - Practice Points
• Indicated in more severe HF:
EF<40%
Symptomatic after ACE Inhibitors
• No loading dose:
Normal RFT: 0.25 mg/day and level in 1 week
Abnormal RFT: 0.125 mg/day and level in 2-3 weeks
• Digoxin toxicity:
Confusion, nausea, anorexia, visual change, arrhythmias
• Digoxin interaction:
Quinidine, verapamil, amiodarone, antibiotics,
anticholinergics
The recent observation that vesnarinone, a new
non-phosphodiesterase inhibitor inotropic agent,
reduces morbidity and mortality in patients with heart
failure requires supporting confirmation studies
before its routine use can be recommended.54 Its
mechanism of action is not fully understood but
postulated to serve as an immunomodulator by
inhibiting cytokines production stimulated by the
failing heart.55'56
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Beta-blockers
Beta-blockers have been postulated in positively
modifying the pathophysiological pathways of
mortality and morbidity in heart failure by reducing
neuroendocrine activation, reduction in' myocardial
ischaemia and suppression of ventricular arrhythmias.
Nevertheless, there has been a widespread reluctance
to use beta-blockers in heart failure for fear of
worsening the congestive heart failure. Certainly,
beta-blockers is indicated in the management of post-
myocardial infarct patients.57"59 In addition, the
impact of beta-blocker in patients with idiopathic
dilated cardiomyopathy has been addressed in one
large randomised trial which showed reduction in
deaths or the need of heart transplantation as well as
less clinical deterioration in heart failure
parameters.60
One of the problems of beta-blocker is the non-
selective beta-2-blocking effects on the arterial tree,
resulting in vasoconstriction and compromisation of
tissue flow. Therefore, beta-blocker with partial
agonistic action may offer a benefit over conventional
ones. In a randomised study performed by our
institution on the use of labetalol61 which possess
alpha-agonist property, there is an increase in
exercise performance compare with placebo. A new
third generation beta-blockade (e.g. Carvediol) has
been developed with combined vasodilatory and
alpha-blockade effects.62"63 Its advantages in
minimising myocardial depression and at the same
time preventing natural progression of heart failure
draw a lot of enthusiasm. Several small studies have
shown improvements in ejection fraction and reduced
left ventricular dimensions with its use, and in
preliminary reports a survival benefit was observed
for all classes of heart failure with the use of
carvediol when compared with placebo54.
Treatment of Refractory Heart Failure
Patients who remain symptomatic with signs of
severe heart failure despite standard therapy for heart
failure represent a serious medical condition with a
very poor prognosis, as many as 50% of these
patients dying within three to six months. Clearly,
the best option is cardiac transplantation. However,
due to the limited capacity of this option, other
strategies have been developed. General supportive
measures form the cornerstone of therapy. These
include salt and fluid restriction, a balanced diet and
rest periods, particularly after meals. The use of
various combination of diuretics has proven useful in
improving some patients with refractory heart failure.
Combination diuretics, such as frusemide, thiazides,
metolazone, triamterene or spirono-lactone can be
very useful. However, the risks of combination
diuretics are not negligible, and include hyper- or
hypokalaemia, hyponatremia and worsening renal
failure. Some reliable patients can regulate their
daily dosage of diuretics according to daily weights
taken at home. Combination of various vasodilators
can also be useful. In addition to ACE inhibitors,
nitrates and hydrallazine can be added to the regimen
but careful monitoring of blood pressure is required
and in some patients, haemodynamic monitoring is
needed to balance optimal therapy against the
hypotensive effects of the agent. During periods of
acute decompensation, intravenous nitroglycerine (1
to 2 ug/kg/min) and dobutamine/ dopamine have been
found to be useful in some patients. However,
patients should be monitored closely for arrhythmias,
electrolyte imbalances and haemodynamic
disturbances. Finally, short-term use of nitroprusside
and amrinone infusions can also be considered as last
resorts (Table 7).
Table 7: Persistent Heart Failure
• Exclude reversible causes:
e.g. compliance, dietary indiscretion, anaemia, infection,
NSAID
• Diuretics
Large dose (e.g. frusemide 480 mg/day)
Intravenous diuretics
Metalozone 2.5 mg single dose
• Spironolactone (beware of hyperkalaemia)
• Hydrallazine/isosorbide
PND: nitrate patch at sleep
• Transplantation
531
(Continued on page 533)
Hong Kong Practitioner 17 (11) November 1995
Surgical Treatment for Heart Failure
Coronary artery disease is a major cause of
heart failure. Although the risk of
revascularisation is increased in patients with
poor left ventricular function and severe
coronary artery disease, long term surgical
survival benefits appear greatest in patients with
the most severe left ventricular function,
coronary disease and anginal symptoms.
Therefore, patients with coronary artery disease
and demonstrable ischaemia should be considered
for revascularisation. A low ejection fraction or
presence of congestive heart failure should be
an indication rather than a contraindication to
surgery.65"68
In patients with potentially resectable left
ventricular aneurysm, aneurysm resection with or
without bypass grafting should be considered,
and in patients with overt heart failure it is
recommended surgery should be performed
before severe irreversible global dysfunction or
acute decompensation occurs.69 In addition,
patients with life threatening ventricular
arrhythmias and coronary artery disease with an
area of resectable scar should be referred for
consideration of map-directed surgical resection
and cure of their ventricular tachycardia at the
time of revascularisation and left ventricular
repair.70 Lastly, the importance of valvular
repair or replacement in the treatment of heart
failure should be remembered.
Cardiomyoplasty is an experimental technique
that may be of benefit in selected groups of
patients with severe congestive heart failure and
dilated cardiomyopathy as a bridge to cardiac
transplantation. In addition, small studies has
shown improvements in functional class and
short term survival with this surgical
technique.71"72
Other forms of ventricular assist devices
(e.g. Heart Mate) and the total artificial heart
are still under clinical trial and the routine use
in clinical practice require further supporting
data.73"74 At present, these are still bridging
devices to maintain the life of patients prior to
cardiac transplantation.
Cardiac Transplantation
The most common indications for heart
transplantation in adults are cardiomyopathy and
coronary artery disease. Outcome has improved
with the introduction of the immunosuppressant
cyclosporine in the early 1980s. Five-year
survival after transplantation now exceeds 70%,
one-year survival is around 88% and the 30-day
mortality is 10% due to graft failure, acute
rejection or infection.75 However, after two
years, accelerated coronary artery disease,
probably on an immune basis, becomes the
leading cause of death; and these patients may
die suddenly as they do not experience angina
because of surgical denervation. In addition,
the accelerated atherosclerosis differs from the
usual variety in that it is more diffuse, distal,
cellular, with less lipid accumulation and
collateral vessels are rare.76"77
Principal selection criteria for candidates
suitable for heart transplantation are intractable
heart failure despite optimal medical therapy and
not amenable to conventional surgery, with a
poor 12-month prognosis and with likelihood of
rehabilitation. Contraindications to heart
transplantation include recent malignancy, recent
drug or alcohol abuse, untreated infection,
irreversible renal disease (creatinine greater than
200 umol/L) or hepatic disease, irreversible
pulmonary hypertension (pulmonary vascular
resistance more than 6 Wood units), surgical
technical factors, noncompliance with medical
care, poor rehabilitation potential, severe
peripheral or cerebrovascular disease, marked
cachexia or obesity, and insulin-dependent
diabetes with end organ disease. With
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experience, the number of absolute
contraindications to heart transplantation have
declined.78-79
Ancilliary Treatment
Anticoagulant therapy is strongly
recommended in all patients with heart failure
and associated atrial fibrillation. However, in
patients who are noncompliance or at risk from
warfarin therapy, aspirin is recommended.
Although anticoagulation is not recommended as
a routine in heart failure patients with sinus
rhythm, it should be considered in patients with
severe LV dysfunction, demonstrated intracardiac
thrombus, or other risks for arterial or venous
thrombosis.80 However, a recent meta-analysis
showed that patients with severe heart failure in
sinus rhythm gain no benefit from
anticoagulation.81 Thus, in an uncomplicated
patient with heart failure, the routine of
anticoagulation, with its inherited risk and the
need for monitoring, is not recommended.
Antiarrhythmic therapy is indicated for
patients with severe symptomatic rhythm
disturbances. Patients with near rniss sudden
death, ventricular fibrillation and sustained
ventricular tachycardia require effective therapy.
Atrial arrhythmias, particularly atrial fibrillation,
can result in significant disability. The use of
antiarrhythmic drugs, however, is not only
generally less effective and associated with
increased risk of proarrhythmic effects in the
setting of heart failure, but are also associated
to a varying degree with negative inotropic
effects, making control of heart failure more
difficult. Drug therapy is recommended only
for life-threatening or significantly symptomatic
arrhythmias. Type I agents (quinidine,
procainamide, disopyramide, flecainide,
propafenone) should be avoided. Type III drugs
such as sotalol and amiodarone are effective and
usually considered first-line agents.82 Recently,
the Grupo de Estudio de la Sobrevida en la
insuficiencia Cardiaca en Argentina (GESICA)
trial suggested that low dose amiodarone can
decrease mortality (both sudden death and death
due to progressive heart failure) and hospital
admission in patients with heart failure in a
population that was mainly represented by dilated
cardiomyopathy.83'84
Patients with severe heart failure have a
significant risk of sudden cardiac death which
may be unpredictable and the routine use of an
implantable cardioverters/defibrillators (AICD) in
such patients is a matter of intensive clinical
research. At present, it is implanted in
patients, as a form of life-saving device, who
are prone to develop haemodynamically unstable
ventricular tachyarrhythmia (as an alternative to
anti-arrhythmic therapy) for the prevention of
sudden cardiac death. With the use of
tranvenous AICD and lower risk of their
implantations, a wider use of such devices are
expected.
Summary
All patients with known or suspected heart
failure should undergo a detailed history and
physical examination. Other causes for the
symptoms and/or clinical signs indicative of
heart failure should be excluded. Routine
biochemical tests, as well as a standard chest x-
ray and ECG, should be performed on all
patients with heart failure. Precipitating or
aggravating causes of heart failure should be
eliminated. Patients with potentially surgically
correctable lesions, such as constrictive
pericarditis, valvular disease or left ventricular
aneurysm, should be referred for cardiological
evaluation and the appropriate surgery. Patients
with ischaemic induced heart failure should be
assessed for possible revascularization by either
angioplasty or bypass surgery. Together with
clinical findings and cardiac diagnostic tests,
appropriate therapy can be allocated accordingly
(Figure 4).84 •
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Figure 4: Management Algorithm of Heart Failure
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